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TUMOUR blood flow is important in the radiotherapy and chemotherapy of
cancer. An inadequate blood supply to a tumour will cause zones oflow oxygen
tension in which the cancer cells will be relatively radio resistant, also, the access
of chemotherapeutic agents to these areas will be poor. Thus information about
factors which alter tumour blood flow could be useful in therapy. It has long
beenknownthat tumour bloodflow is ofteninadequate andthat the tumourvessels
are sufficiently abnormal to form a weak link in tumour organisation. Attempts
could be made to exploit this therapeutically if our knowledge of the physiology
and pathology of tumour vessels were adequate.
Cater, Grigson and Watkinson (1962) found that changes of systemic blood
pressure were often followed, within a few seconds, by similar changes in tumour
blood flow (as indicated by tumour oxygen tension). But there were notable
exceptions to this rule. Intravenous injection of noradrenaline, or adrenaline,
markedly raised the bloodpressure but caused a rapid but temporaryfall oftumour
oxygen tension; and 5-hydroxytryptamine (5-HT) caused only a slight fall of
blood pressure but the tumour blood flow ceased for an hour or more with a dose
(5 mg. base/kg. i.p.) that had little or no effect on the muscle circulation. Cater,
Schoeniger and Watkinson (1963) proved that 5-HT had in fact stopped the blood
flow in rat and mouse tumours because following its injection oxygen inhalation at;
hyperbaric pressures of 5 atmospheres absolute failed to produce a rise of tumour
oxygen tension. This evidence indicated that tumour vessels might be unduly
sensitive to circulating physiological amines.
In the investigation reported here the oxygen cathode/oxygen-inhalation
technique for assessing changes of tumour blood flow has been used to screen a
number of vaso-active drugs (given by slow perfusion apparatus) for possible
useful effects upon tumour bloodflow. The vasoconstrictors adrenaline, noradren-
aline, hypertensin, the ganglion stimulating agent dimethyl-phenyl-piperazine
(DMPP), and the vasodilators isoprenaline, acetyl choline, nicotinic acid, and
amyl nitrite were studied. Acetyl choline gave a small, definite vasodilator effect,
but the failure to find vaso-active drugs with dramatic effects on tumour circula-
tion comparable with those of 5-HT suggested another line of reasoning. 5-HT
is an important initiator of the inflammatory reaction, especially in rats and mice
the species in which the effect of5-HT on tumour circulation hadbeen investigated.
Tumours are often well supplied with factors likely to produce inflammation-
anoxia, necrosis and infection. Therefore it seems likely that chemical substances
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which cause inflammation and particularly those which initiate or maintain the
inflammatory process-the so-called " mediators " ofthe inflammatory reaction-
might have a bigger effect on tumour vessels and tumour blood flow than on the
circulation ofnormal tissues. Bradykinin, bradykinin derivatives andthe enzyme
kallikrein which produces bradykinin and other kinins in the tissues have been
implicated as important mediators of the inflammatory reaction (Rocha e Silva,
1964 and Lewis, 1964). These drugs afforded an opportunity of testing the
hypothesis that tumour vessels are unusually susceptible to inflammatory agents.
The effects of bradykinin and kallikrein on the oxygen tension of tumours are
described here. The parallel experiments using the Pelikan ink technique of
Majno, Palade and Schoefl (1961) for detecting vessels undergoing inflammatory
changes are described in the following paper (Cater and Taylor, 1966).
METHODS
August strain rats with hepatoma 223 transplanted into left leg were used for
all experiments 7-14 days after injection. The rats were anaesthetised with
urethane 6 ml./kg. ofa 25% w/v solution injected subcutaneously. An hour later
tracheotomy and carotid cannulation were performed. The polythene cannula
contained <0 1 ml. of saline with 60 units/ml. of heparin and was connected to
a mercury manometer of 2 mm. bore.
Gold-plated stainless steel electrodes made by the method of Cater and Silver
(1961) were inserted into the tumour and muscle. The amplifier circuit, switch
gear and calibration techniques used were those described by Cater, Silver and
Wilson (1959). The experimental set up and recording was that described by
Cater, Grigson and Watkinson (1962). A " Palmer slow-infusion machine "
made by C. F. Palmer (London) Ltd. was used for injections into the lateral tail
vein ofthe rat.
In some ofthe later bradykinin experiments a polythene tube was tied into the
right iliac artery.
At the end ofthe experiments rats were killedwith chloroform, and 10% formal
saline was injected i.v. The next day the tumour was removed and allowed to
remain in formal saline for some days with the electrodes still in sitU. After wax
embedding, serial sections were cut, stained and examined to determine the
precise positions of electrodes.
Drugs used
Noradrenaline (1: 1000) Levophed, Bayer Products Ltd.
Adrenaline B.P., Martindale Samoore Ltd.
Isoprenaline sulphate B.P., Burroughs Wellcome.
Nicotinic acid (sodium salt, 100 mg./2 ml. ampoules), Savory & Moore.
Dimethyl-phenyl-piperazine (DMPP), Parke Davis & Co., Research Division
(Lot 4982-x19)
Hypertensin (CIBA 0 5 mg. per ampoule)
Acetyl choline, B.D.H.
Amyl nitrite, BPC, Savory & Moore Ltd.
Bradykinin (0.1 mg./ml., Synthetic Bradykinin, Sandoz).
Kallikrein, " Glumorin " (10 i.u. per ampoule for intramuscular injection),
Bayer.
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RESULTS
Effect of vasoconstrictors on tumour and muscle oxygen tension
1. Noradrenaline. Single intravenous doses of 5 ,ug./kg. always caused a
marked but transient fall oftumour oxygen tension (Cater, Grigson andWatkinson,
1962). Slow perfusion of 20 ,tg./kg./min. i.v. for 15 minutes was given to see if
this would produce a different type of response, but as the noradrenaline took
effect and raised the blood pressure the tumour oxygen tension tended to fall
while that of the muscle rose quite markedly. The results suggest that nor-
adrenaline with its vasoconstrictor effect on peripheral vessels tends to reduce
tumour blood flow and the findings are more significant when the considerable
rise of blood pressure and muscle oxygen tension are taken into consideration.
2. Adrenaline. 5 ,ug./kg. given as a single dose (Fig. 1) caused a big rise in
blood pressure and a fall in tumour oxygen tension. The muscle oxygen tension
often rose. When given by slow perfusion at 2 ,tg. to 8 ,ag./kg./min. i.v. for
16 minutes, the results were more variable, possibly depending on the blood
pressure level and the previous treatment; in two experiments there was a rise of
tumour oxygen tension, in two a fall. Thus there is the possibility of increased
blood flow in the tumour, presumably because the rise ofblood pressure caused by
adrenaline is more due to increased cardiac ouitput than to vasoconstriction.
In one experiment noradrenaline caused a fall of oxygen tension in tumour and
adrenaline caused a rise.
3. Dimethyl-phenyl-piperazine (DMPP). A ganglion stimulating agent was
used in 12 experiments, in 9 ofthese it was the first treatment given. There were
adequate blood pressure records in 10 experiments. In the first experiment,
trial-doses of 250 ,tg./kg., 500 ,ug./kg. and 125 ,ug./kg.-a total of 875 ,ug./kg.
were given without obvious ill effects, but for the other experiments doses of 170
to 235 jag./kg. were given sometimes repeated once. The results were rather
variable and seemed to depend on the initial blood pressure. If this was below
80 to 90 mm.Hg injection ofDMPP caused a rise ofblood pressure and the tumour
oxygen tension tended to follow the blood pressure and the response to oxygen
inhalation was usually better. Fig. 2 (first half) shows an experiment in which
both tumour and muscle oxygen tension tend to follow the blood pressure changes.
In some experiments the muscle oxygen tension fell as that ofthe tumour rose and
the response in the muscle to oxygen inhalation was smaller (as shown in Fig. 2).
However, if the blood pressure was more than 90 mm.Hg when the DMPP was
given the response varied from no change of blood pressure, or small variations
about the mean, to a fall. Again the tumour oxygen tension tended to follow
the blood pressure changes and the muscle oxygen tension fell.
4. Hypertensin-a polypeptide with pressor properties was used in 4 experi-
ments. In two experiments in which 10 ,tg./kg./min. was given as the first
treatment theelectrodeswerefound onhistological examination tobeinthetumour
capsule. The hypertensin caused a big rise of blood pressure and the oxygen
tension ofthe tumour capsule gave a biphasic response rising at first as the blood
pressure rose and then falling. In two more experiments the hypertensin was
given afterkallikrein (seebelow) and inretrospect it is nowrealised thatthetumour
was still probably undergoing bradykinin-like changes when the hypertensin was
given.
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Fie. 1.-Changes of systemic blood pressure and oxygen tension in muscle (----)and
tumour ( -) after injection of adrenaline 5pg./k&g.i.v. Note response to oxygen
inhalation before and after theinjection. The adrenaline caused alarge rise ofblood pressure
but the tumour oxygen tension fell, while that of the muscle showed a temporary rise.
(T.W. = warming of tail to make injection feasible).
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FIG. 2. Changes of systemic blood pressure and oxygen ternsion in muscle --- - -) and
tumour ( ) after DMPP 215 and 180 ,ug./kg.i.v. and slow-perfusion ofacetyl choline
2, 4, 8 and 16 ,cg./kg./min.
With DMPP the oxygen tension ofmuscle and tumour appear to change with systemic blood
pressure. Acetyl choline raised the oxygen tension of muscle and tumour and the response
to oxygen inhalation was definitely increased in the tumour.
Effect of vasodilators on tumour and mnUcle oxygen tension
5. Isopropylnoradrenaline (Isoprenaline) was used in 11 experiments, as a
first treatment in 4, as a second treatment in 7, in one after hypertensin and in 6
afterbradykinin. In two experiments isoprenaline given intravenously in doses of
157 Fug./kg./min. and 180 ,ug./kg./min. produced a rapid fall of oxygen tension in
tumour and tumour capsule, commencing within 1 minute and falling 80 or 90%
to reach very low levels in 2 or 3 minutes. The blood pressure changes syn-
chronised with these oxygen tension changes. The oxygen tension ofthe muscle
also fell but tended to recover within a few minutes, and this took place before the
isoprenaline perfusion was stopped and before the blood pressure had begun to
rise. In another pilot experiment isoprenaline given after bradykinin abolished
the response ofthe tumour oxygen tension to oxygen inhalation. It was therefore
decided (a) to study the effect ofisoprenaline at different dose levels starting with
very much smaller doses and (b) to study the effect of isoprenaline given after
bradykinin. The results of this latter investigation did not,confirm the original
finding which we now realise was due to a low blood pressure produced by the
combined effects of bradykinin and isoprenaline.
Concerning the study of isoprenaline at different dose-rates, Table I shows the
smallest dose-rates producing definite effects. The tumour oxygen tensions are
low after bradykinin (see below) but fall still furtherwith isoprenaline at dose-rates
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TABLE I.-Smallest Dose Rates ofIsoprenaline with which
Effects were Obtained.
Isoprenaline
Experiment dose
number pg./kg./min. Muscle Tumour Tumour capsule
6 3-5 21->19-4 20-+7
7 11 25 -a3 15 -> 13-2
After hyper-
tensin
8 23-3 13 -+ 11-5 39 -+ 15-5
After
bradykinin
26 6-3 3-6 5 11 - 9-7
34A 11-4 11-5 12-7 29 532 -> 26
B 22-8 13 -- 15 31 - 1-5
38A 12 12-5 -; 13 0 -> 0 2 11-4 11-4
B 48 13 -*14 0 2 0-2 11-4 10
30 28-3 11-5 -l 115--> 8-5 15 - 10 --* 7-5
33A 20-5 31 -+ 31 0 ° 07 16-> 20-> 18
B 41 30 - 275- 0 7 -+ 07 17*5 -* 10-5 -* 9-3
35 39 10-7 - 9 2 7->2-1
Dotted arrow indicates fall tcok place after isoprenaline infusion had been stopped.
(pg./kg./min.) of 11, 6-3, 12, 20.5 and 39. The oxygen tension in tumour capsule
is higher than that in tumour and falls with isoprenaline at somewhat higher
dose-rates, 3 5, 23-3, 22-8, 48, 28-3, 41, ,ug./kg./min. Note that in experiments
38 and 33 the tumour is effected at half the dose-rate required to produce a con-
vincing fall of oxygen tension in the tumour capsule. The muscle responds in a
different fashion because dose-rates of isoprenaline which caused falls of oxygen
tension in tumour or tumour capsule produce a rise ofmuscle oxygen tension in 6,
no change in 2 and a fall in 4. The falls were slight compared with those oftumour
capsule. Analysis of the blood pressure changes suggests that this could be the
determining factor. A dilatation of the muscle vessels compensating or partially
compensating for lowering of the systemic blood pressure would account for the
rise of muscle oxygen tension seen in some experiments. The fall of oxygen
tension ofthe tumour and tumour capsule would be explained by the fall in blood
pressure causing decreased blood flow in these areas.
6. Acetyl Choline. Acetyl choline was given in 9 experiments, as a first treat-
ment in 3, after noradrenaline on 1, and after DMPP in 5 experiments. The
effect of giving acetyl choline appeared to be the same when given after DMPP
as when given as the primary treatment. Acetyl choline given i.v. by slow
perfusion produced a small but definite increase of tumour oxygen tension and an
increased response to oxygen inhalation. These findings indicate an increased
tumour flow with acetyl choline. A similar effect occurred in muscle but at a
higher dose-rate. The change in tumour was greatest at small dose-rates of
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1*8 itg. to 4 ,ug./kg./min. Dose-rates of 4-5 to 10-5 ,ug./kg./min. also increased
tumour oxygen tension and sometimes gave a greater response to oxygen inhala-
tion, but in 5 experiments this was lower than the response obtained with the
smaller dose. Higher dose-rates up to 21 jtg./kg./min. were less effective in
increasing the blood flow through the tumour but were more effective in increasing
that ofmuscle. In ourexperimentstherewaslittle change ofbloodpressureduring
the injection of acetyl choline. Fig. 2 shows a typical experiment and it will be
seen that a dose-rate of 4 ,ug./kg./min. increased the tumour oxygen tension and
the response to breathing oxygen compared with that obtained at the beginning
of the experiment. The response is even greater at a dose-rate of 8 ,tg./kg./min.
There was some increase of muscle oxygen tension with the rat breathing air
and the response to breathing oxygen increased as the dose-rate of acetyl choline
wasincreased. Datafrom the otherexperimentswouldsuggestthatthe maximum
effect on the muscle would be expected at a higher dose-rate than 8 ,tg./kg./min.
7. Nicotinicacid wasusedin 4experiments. Given assingledosesof55 mg./kg.
to 250 mg./kg. i.v. it caused little change in blood pressure. The muscle blood
flow was improved, as judged by oxygen tension levels and the response to oxygen
inhalation, but that of the tumour showed signs of improvement in two experi-
ments and the reverse in two.
8. Amyl nitrite. The results obtained confirmed our previous experience that
electrodes sited in tumour always showed a fall ofoxygen tension during the fall of
blood pressure produced by inhalation of amyl nitrite. The response of muscle
oxygen tension varied from little or no change to a fall, but the fall was always
relatively less than that in tumour. Electrodes sited in tumour capsule tended
to conform to the muscle response. Amyl nitrite inhalation was in fact often
used at the end of an experiment as a functional test of the site ofthe electrode.
The fall ofoxygen tension in tumour was probably due to the fall ofblood pressure
reducing tumour blood-flow. Evidence in favour of this view came from one
most unusual experiment in which the blood pressure was very low and amyl
nitrite caused a rise of blood pressure and a rise of tumour oxygen tension.
Presumably the rise ofblood pressure was due to amyl nitrite increasing the output
of a failing heart.
Effects of some "mediators " of the inflammatory reaction on tumour and muscle
oxygen tension
None of the vaso-active drugs described above produced effects on tumour
circulation comparable with those produced by 5-HT, therefore other mediators
of the inflammatory reaction were studied to see whether they would produce
effects on tumour blood-flow.
9. Effect of Bradlykinin on tumour and muscle oxygen tension. Bradykinin is
now thought to be an important mediator ofthe inflammatory reaction, therefore
its effect on tumour oxygen tension was carefully studied in 12 experiments using
graduated doses by slow-perfusion intravenously or intra-arterially. A typical
experiment is shown in Fig. 3 and it will be noted that small dose-rates ofbrady-
kinin resulted in a fall oftumour oxygen tension and a reduction ofthe response to
inhalation ofoxygen. The oxygen tension ofmuscle showed little change at first,
with some moderate reduction near the end of the treatment and for 15 minutes
afterwards. However, the response to oxygen inhalation was not affected. The
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FIG. 3.-Changes ofsystemic bloodpressure and oxygentension inmuscle (-- - -) and tumour
) before, during, and after slow perfusion of bradykinin 0-325, 0-65, 1-3 and 2-6
pg./kg./min. The tumour oxygen tension falls and becomes less responsive to inhalation
ofoxygen during bradykinin injection, and afterwards the recovery is incomplete.
low initial level of oxygen tension in tumour and a level of about 12 mm.Hg in
muscle are typical.
Theexact site oftheelectrodetip was checkedbyserialsections and 7 electrodes
were found to be in muscle adjacent to tumour tissue. These were designated
electrodes in tumour capsule and showed .a quite different response, which is
illustrated in Fig. 4. The tumour capsule shbwed a rise ofoxygen tension during
the slow injection of bradykinin. The response to oxygen inhalation was also
increased and these effects also persisted for some minutes after the treatment.
Note that the level of oxygen tension was higher in the tumour capsule than the
tumour. In this experiment the muscle electrode was near to vessels and was
higher than average. There was a slight rise with the bradykinin but the response
to breathing oxygen was not so good.
In the 12 experiments records were obtained on 7 electrodes in tumour, and
4intumour capsule duringi.v. injection and 4electrodes intumourand 3 intumour
capsule duringintra-arterial injection. No obviousdifferences werefoundbetween
intravenous and intra-arterial administration of the drug so the results from all
experiments have been combined for analysis and records from 9 electrodes in
normal muscle were available for comparison. The mean oxygen tensions before,
during and after bradykinin treatment are shown in Table II, also the levels
A 00
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FIG. 4.-A parallel experiment to Fig. 3, but the electrode was in tumour capsule and this shows
an increase ofoxygen tension and an increased response to oxygen inhalation during the slow
perfusion of bradykinin.
TABLE II.-Mean Oxygen Tensions in mm. of Hg of Tumour, Turmour Capsule
and Muscle Before, During and After Infusion of Bradykinin (a) Breathing
Air and (b) Breathing Oxygen.
(a) Breathing Air.
Before treatment
During bradykinin
After treatment
(b) Breathing Oxygen
Before treatment
During bradykinin
After treatment
Tumour
6-9 ± 1-8 (11).
4-85 ± 1*75(11).
5-4 ± 1-6 (11) .
14-7 + 3-7 (11)
12- 7 ± 3.9 (11)
13-6 ± 4 9 (9)
Tumour capsule
15-6 ± 3*0 (7)
18-2 ± 3-6 (7)
16-7 ± 3.5 (7)
48-3 ± 14-9 (7)
48-8 ± 10 7 (7)
43-3 ± 7-4 (7)
Muscle
16-3 ± 26 (9)
15-2 ±2.8(9)
14-4 ± 2- 9 (9)
46-25 ± 8-5 (9)
44-8 ± 7-4 (9)
44-4 ± 6-9 (8)
reached during oxygen inhalation. Note that the mean oxygen tension of the
tumour and its response to oxygen inhalation is significantly less than that of
tumour capsule and muscle. As each electrode acts as its own control it is legiti-
mate to take the reading when air is breathed before the treatment as 100% and
it then appears thatfall oftumour oxygentensionduring bradykinin is a significant
change of - 391 ± 8 4% and the rise ofoxygen tension in the tumour capsule is a
significant change of + 21-4 + 6.4%. The difference between the tumour and
tumour capsule is highly significant t = 5 7, n = 17, P < 0-001. The detailed
changes are shown in Table, II. It is also noteworthy that tumour capsule and
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TABLE III.-Percentage Changes of Oxygen Tension of Tumour, Tumour Capsule
and Muscle, During and AfterInfusion ofBradykinin (a) Breathing Air and (b)
Breathing Oxygen; Taking the Value given by each Electrode Before Treatment
as 100%.
(a) Breathing Air
During bradykinin
After bradykinin
(b) Breathing Oxygen
During bradykinin
After bradykinin
Tumour
. -39 1 ± 840%
. -32 8 ± 9.7%
Tumour capsule
+ 21 4 ± 640% + -14 ± 11%
-16-4 ± 47% . +1341 + 950%
-3-1 ± 1740% . +5364 ± 410%
Muscle
- 9 8 ± 5-5%
-15-4 ± 9 60%
+ 76 ± 13.50%
. - 1*6 i 210%
muscle are significantly different during bradykinin injection t = 3.7, n = 15,
p < 0 01, > 0-001. After the bradykinin treatment the tumour and tumour
capsule are still significantly different t 3419, n - 17, p < 0 01, > 0 001.
10. Effect ofkallikrein on tumour and muscle oxygen tension.-Kallikrein in vivo
liberates bradykinin and other kinins and itseffects, as would be expected, resemble
those of bradykinin. Fig. 5 shows a typical experiment in which lOi.u./kg.
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FiG. 5-Changes of systemic blood pressure and oxygen tension in muscle (...................................... ) and
two parts of the tumour ( ) and (.- * ) after injection of kallikrein 10 i.u./kg. i.v.
There was a long slow fall of tumour oxygen tension. The injection of hypertensin 10 and
20 ,ug./kg./min. i.v. produced temporary and irregular rises of tumour oxygen tension.
Oxygen inhalation at the end of the experiment indicated still further deterioration in
blood-flow.
given i.v. produced a long, slow fall of oxygen tension in tumour and a progressive
deterioration in the response to oxygen inhalation. Muscle oxygen tension and
blood pressure were also affected and hypertensin was given at. the end of the
experiment to try and correct this. In retrospect we realised that the effect of
kallikrein was long lasting and probably irreversible so that little attention should
be paid to the effect of hypertensin-. The effects of kallikrein on tumour vessels
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have been studied in greater detail by Cater and Taylor (1966) using the Pelikan
ink technique.
DISCUSSION
The investigation falls into two sections. First the search for vaso-active
drugs with useful effects on tumour circulation, namely either to increase it for
radiotherapy and chemotherapy or to damage tumour vessels for a direct thera-
peutic attack on the tumour. Secondly a more detailed study of the effects of
mediators ofthe inflammatory reaction on tumour blood flow to prove or disprove
the hypothesis that tumour vessels are especially sensitive to inflammatory
agents.
Part one extended the work of Cater, Grigson and Watkinson (1962) on vaso-
active drugs using the more refined technique of slow intravenous injection and
spreading the net wider to include more drugs. In general the findings amply
confirmed the earlier conclusions that tumour blood-flow varies directly with
systemic blood pressure but that the effects of the physiological amines produce
notable exceptions to this rule. Amyl nitrite, for instance, lowers the blood
pressure and the tumour oxygen tension but has no effect, or much less effect, on
that of muscle. In one, most unusual experiment amyl nitrite raised temporarily
a very low blood pressure and this was paralleled by a temporary rise of tumour
oxygen tension. In contrast noradrenaline, which in acute i.v. doses always
caused a temporary rise of blood pressure always caused an equally transient
fall of tumour oxygen tension. Noradrenaline given by slow perfusion gave
comparable results, i.e. we did not find a dose-rate which raised tumour oxygen
tension. Adrenaline in acute doses i.v. always raised the blood pressure and
dropped the tumour oxygen tension, but with slow perfusion there did appear to
be the possibility of raising the tumour oxygen tension. As adrenaline often
raises the blood pressure by increasing cardiac output rather than by vasocon-
striction we expected that a beneficial effect on tumour blood flow might be
obtainable. However, dose-rate is obviously critical and in half the experiments
a fall oftumour oxygen tension occurred in spite ofthe rise ofblood pressure. It is
doubtful, therefore, whether adrenaline would be useful clinically in radiotherapy
and its other effects might be undesirable in a cancer patient. The effects of
DMPP were also too variable to offer much hope of exploitation in radiotherapy,
and hypertensin did not produce any promising effects.
Turning to vasodilators - isoprenaline lowered the blood pressure and often
raised the oxygen tension in muscle, at least to begin with. The results were
consistent with vasodilation and improved muscle blood-flow, but the lowering of
the blood pressure also lowered the oxygen tension of tumour and tumour capsule
at dose-rates of 3-5 to 48 ,ug./kg./min. The tumour was affected by somewhat
lower dose-rates than the tumour capsule. Isoprenaline causes hyperpyrexia and
hyperventilation and these undesirable effects together with hypotension would
also mitigate against any useful role in radiotherapy.
The rise of tumour oxygen tension and response to oxygen inhalation during
slow perfusion ofacetyl choline can be interpreted as a small but definite increase
in tumour blood-flow. These changes occurred at the smaller dose-rates used,
1.8 to 4 ,ug./kg./min., while the higher dose rates, 10 5 to 21 ,tg./kg./min., were
more effective in increasing the blood-flow in muscle but were less effective on the
tumour. Acetyl choline is rapidly destroyed in the bodv and it would be
514VASOMOTOR AND INFLAMMATORY AGENTS AND BLOOD FLOW
interesting to repeat these experiments after an esterase inhibitor. Our findings
confirm those of G'ullino and Grantham (1962) who measured tumour blood-flow
directly in " tissue-isolated tumour transplants " using 5 to 20 ,ug. acetyl-,3-methyl
choline chloride per rat as an acute dose either i.v. or injected direct into tumour
tissue. With the latter technique they obtained a considerable increase oftumour
blood-flow.
We may conclude that tumour blood-flow is considerably altered by the circu-
latinghormones, noradrenaline, adrenaline, isoprenaline, acetyl cholineandbecause
these changes take place in the absence of or in spite of blood pressure changes
there is clear evidence that the hormones must affect the tumour blood vessels.
The second part of the investigation concerned the hypothesis that tumour
vessels respond more actively thannormal vessels tomediators oftheinflammatory
reaction. There is no doubt that 5-HT profoundly alters tumour blood-flow in
doses which do not affect muscle circulation or have only a mild effect upon it
(Cater, Grigson and Watkinson, 1962; Cater, Schoeniger and Watkinson, 1963;
Cater, Petrie and Watkinson, 1965). To this we may now add that bradykinin
produces a definite fall of tumour blood-flow in spite of producing a definite
increase in the blood-flow of the tumour capsule. (The tumour capsule consists
ofaltered muscle but also contains new vessels and dilated vessels. It behaved in
a statistically different fashion from normal muscle. These observations are
consistent with the contention ofZweifach (1964) that bradykinin acts essentially
as a dilator of arterioles).
Bradykinin is very quickly destroyed in blood but the effect ofthe bradykinin
on the tumour lasted after the perfusion had ceased and probably indicates that
changes had been produced in the vessels. This would accord with the findings
of Cater and Taylor (1966) who showed by the Pelikan ink technique of Majno,
Palade and Schoefl (1961) that bradykinin produced inflammatory changes in
tumour vessels.
Kallikrein also produced falls in tumour oxygen tension and reduced the
response to oxygen inhalation which indicated a long lasting reduction oftumour
blood-flow. As kallikrein produces bradykinin in vivo, together with other kinins,
this result was not surprising and helps to confirm the results obtained using
bradykinin.
The problem ofthe action on tumour vessels ofthe mediators ofthe inflamma-
tory reaction will be discussed in greater detail in the subsequent paper by Cater
and Taylor (1966).
SUMMARY
Tumour blood-flow changes, assessed by oxygen tension measurements and
response to oxygen inhalation, often tended to mimic changes of systemic blood
pressure except after injection of noradrenaline, adrenaline, or 5-hydroxytrypta-
mine (5-HT). Noradrenaline, given by slow-perfusion, always raised the blood
pressure but reduced tumour blood-flow. Adrenaline raised the blood pressure
but the effects upon the tumour blood-flow were variable. The ganglion-stimu-
lating agent dimethyl-phenyl-piperazine (DMPP) gave variable results as did
hypertensin. Vasodilators studied included acetyl choline which increased
tumour blood-flow, nicotinic acid gave variable results, while isoprenaline and
amyl nitrite both decreased tumour blood-flow.
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The inflammatory agents :-(1) 5-HT, stops tumour blood-flow; (2) brady-
kinin, reduces blood-flow in tumour but increases it in tumour capsule; (3)
kallikrein (which produces bradykinin in vivo) has a similar effect.
We wish to thank, Air. E. King ofthe Department ofRadiotherapeutics for the
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